{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:16:27Z","timestamp":1790622987669,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:00:00Z","timestamp":1567728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Cardiovascular Interventions"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.jcin.2019.07.059","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T16:00:32Z","timestamp":1575302432000},"page":"2346-2355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post\u2013PCI in Patients With\u00a0Atrial Fibrillation and Diabetes"],"prefix":"10.1016","volume":"12","author":[{"given":"Michael","family":"Maeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan H.","family":"Hohnloser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matias","family":"Nordaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Miede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Oldgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurri\u00ebn M.","family":"ten Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcin.2019.07.059_bib1","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.2337\/dc16-2388","article-title":"Patients with diabetes without significant angiographic coronary artery disease have the same risk of myocardial infarction as patients without diabetes in a real-world population receiving appropriate prophylactic treatment","volume":"40","author":"Olesen","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcin.2019.07.059_bib2","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/eci.12804","article-title":"Coronary artery disease and risk of adverse cardiac events and stroke","volume":"47","author":"Olesen","year":"2017","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jcin.2019.07.059_bib3","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.amjcard.2010.01.007","article-title":"Long-term outcomes after percutaneous coronary intervention in patients with and without diabetes mellitus in western Denmark","volume":"105","author":"Jensen","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jcin.2019.07.059_bib4","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr488","article-title":"Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study","volume":"33","author":"Friberg","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2019.07.059_bib5","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1161\/STROKEAHA.115.009371","article-title":"Duration of diabetes mellitus and risk of thromboembolism and bleeding in atrial fibrillation: nationwide cohort study","volume":"46","author":"Overvad","year":"2015","journal-title":"Stroke"},{"key":"10.1016\/j.jcin.2019.07.059_bib6","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2019.07.059_bib7","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1016\/j.jacc.2018.08.1046","article-title":"CAD is an independent risk factor for stroke among patients with atrial fibrillation","volume":"72","author":"Steensig","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2019.07.059_bib8","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2019.07.059_bib9","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/clc.22572","volume":"39","author":"Cannon","year":"2016","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.jcin.2019.07.059_bib10","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/europace\/euy174","volume":"21","author":"Lip","year":"2019","journal-title":"Europace"},{"key":"10.1016\/j.jcin.2019.07.059_bib11","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2019.07.059_bib12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijcard.2015.05.141","article-title":"Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: results from the RE-LY trial","volume":"196","author":"Brambatti","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jcin.2019.07.059_bib13","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","article-title":"Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial","volume":"65","author":"Fiedler","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jcin.2019.07.059_bib14","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jcin.2019.07.059_bib15","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2019.07.059_bib16","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/eurheartj\/ehy162","article-title":"Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials","volume":"39","author":"Golwala","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcin.2019.07.059_bib17","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jcin.2019.07.059_bib18","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jcin.2019.07.059_bib19","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/CIRCULATIONAHA.118.034722","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention","volume":"138","author":"Angiolillo","year":"2018","journal-title":"Circulation"}],"container-title":["JACC: Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879819318515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936879819318515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:10:27Z","timestamp":1761847827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936879819318515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":19,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S1936879819318515"],"URL":"https:\/\/doi.org\/10.1016\/j.jcin.2019.07.059","relation":{},"ISSN":["1936-8798"],"issn-type":[{"value":"1936-8798","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post\u2013PCI in Patients With\u00a0Atrial Fibrillation and Diabetes","name":"articletitle","label":"Article Title"},{"value":"JACC: Cardiovascular Interventions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcin.2019.07.059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}